Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) has issued an announcement.
On October 20, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into a binding term sheet with 1542770 BC Ltd. to acquire substantially all of Molecule’s assets and liabilities for $10 million, payable in cash and company stock, contingent on certain milestones. Earlier, on October 15, 2025, Shuttle received a termination notice from Theradex Systems, Inc., its primary contract research organization, demanding payment of $1.091 million and threatening to cease services if unpaid within 30 days, highlighting potential operational disruptions.
Spark’s Take on SHPH Stock
According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.
Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.
To see Spark’s full report on SHPH stock, click here.
More about Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry, focusing on developing and providing regulatory and clinical research services through its subsidiary, Shuttle Pharmaceuticals, Inc. The company collaborates with contract research organizations to advance its research and development efforts.
Average Trading Volume: 122,849
Technical Sentiment Signal: Sell
Current Market Cap: $3.94M
Find detailed analytics on SHPH stock on TipRanks’ Stock Analysis page.